AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7870008 — intervention group
Group type: EXPERIMENTAL
Intervention: Never treated with chemoantibiotics
Number of subjects: 6
Study 2693994 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 0
Study 2693994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 349324 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexoprenaline sulphate (1 mg)
Number of subjects: 20
Study 349324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31407629 — intervention group
Group type: EXPERIMENTAL
Intervention: TPOAb-positive women
Number of subjects: 825
Study 31407629 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 treatment
Number of subjects: 825
Study 31407629 — intervention group
Group type: EXPERIMENTAL
Intervention: TPOAb-positive women receiving T4
Number of subjects: 825
Study 31407629 — intervention group
Group type: COMPARATOR
Intervention: TPOAb-negative women
Number of subjects: 825
Study 28438447 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 108
Study 28438447 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 108
Study 25275341 — intervention group
Group type: COMPARATOR
Intervention: Enzyme combination (XB)
Number of subjects: 192
Study 25275341 — intervention group
Group type: COMPARATOR
Intervention: All additives (EO, XB, EO+XB)
Number of subjects: 192
Study 25275341 — intervention group
Group type: COMPARATOR
Intervention: Essential oils (EO)
Number of subjects: 192
Study 25275341 — intervention group
Group type: COMPARATOR
Intervention: Essential oils + enzyme combination (EO+XB)
Number of subjects: 192
Study 22696139 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballot box survey method
Number of subjects: 0
Study 22696139 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized response survey method
Number of subjects: 0
Study 22696139 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face survey method
Number of subjects: 0
Study 22729296 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin at 12.5% (400 ml 6 hours before and 200 ml 2 hours before)
Number of subjects: 40
Study 22729296 — intervention group
Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 40
Study 20667838 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up (TFU)
Number of subjects: 56
Study 20667838 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study 17978033 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo administered after precompetition training with morphine
Number of subjects: 0
Study 17978033 — intervention group
Group type: COMPARATOR
Intervention: Morphine administered during precompetition training
Number of subjects: 0
Study 15726333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cocaine (0, 8, 16, and 32 mg per 70 kg)
Number of subjects: 8
Study 15726333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 8
Study 12192632 — intervention group
Group type: COMPARATOR
Intervention: Physician-supervised smoking cessation program with nicotine replacement and brief intervention; Group A (no stress reduction)
Number of subjects: 140
Study 12192632 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-supervised smoking cessation program with nicotine replacement, brief intervention, and 20-hour stress reduction program over 8 weeks; Group B
Number of subjects: 140
Study 9432177 — intervention group
Group type: COMPARATOR
Intervention: Control (no device)
Number of subjects: 71
Study 8088113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index dietary advice
Number of subjects: 51
Study 2783530 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical vein oxytocin
Number of subjects: 50
Study 2783530 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 50
Study 15903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraamniotic prostaglandin F2alpha (50 mg single dose)
Number of subjects: 50
Study 15903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraamniotic prostaglandin F2alpha (25 mg repeated dose)
Number of subjects: 50
Study 15903 — intervention group
Group type: COMPARATOR
Intervention: Intraamniotic hypertonic saline
Number of subjects: 50
Study 31653353 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienopyridine interruption
Number of subjects: 23002
Study 28097268 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy
Number of subjects: 189
Study 28097268 — intervention group
Group type: COMPARATOR
Intervention: Rigid cystoscopy
Number of subjects: 189
Study 26312582 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted sitting (3 min of moderate-intensity walking every 30 min)
Number of subjects: 28
Study 26312582 — intervention group
Group type: COMPARATOR
Intervention: Continuous sitting
Number of subjects: 28
Study 22572805 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0
Study 22572805 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate
Number of subjects: 0
Study 22572805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21848797 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily
Number of subjects: 219
Study 21848797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 21848797 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 219
Study 19332204 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial PCI with maximal antiplatelet therapy (aspirin and clopidogrel, 70 U/kg heparin, abciximab before first balloon inflation)
Number of subjects: 1348
Study 19332204 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1348
Study 16494145 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 3‐in‐1 femoral nerve catheter with 0.15% ropivacaine (Group A)
Number of subjects: 55
Study 16494145 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 3‐in‐1 femoral nerve catheter with 0.2% ropivacaine (Group B)
Number of subjects: 55
Study 16494145 — intervention group
Group type: COMPARATOR
Intervention: Patient controlled intravenous morphine (Group C - control group)
Number of subjects: 55
Study 16494145 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of groups A and B
Number of subjects: 55
Study 16494145 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of all groups
Number of subjects: 55
Study 12934417 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-circuit anesthesia (CCA)
Number of subjects: 50
Study 11104393 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate analysis adjusted for center effect
Number of subjects: 0
Study 11104393 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted squares of means analysis
Number of subjects: 0
Study 11104393 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual maximum likelihood (REML) estimation
Number of subjects: 0
Study 9244901 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulse oscillometry (IOS) in lateral lying position
Number of subjects: 20
Study 9244901 — intervention group
Group type: COMPARATOR
Intervention: Impulse oscillometry (IOS) in sitting position
Number of subjects: 20
Study 9244901 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulse oscillometry (IOS) measurements
Number of subjects: 20
Study 9244901 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulse oscillometry (IOS) in lying position
Number of subjects: 20
Study 8445231 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pulse prednisone therapy (90 mg daily for 5 days each month)
Number of subjects: 16
Study 8445231 — intervention group
Group type: COMPARATOR
Intervention: Conventional daily dose therapy with prednisone in combination with azathioprine
Number of subjects: 16
Study 8445231 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pulse prednisone therapy
Number of subjects: 16
Study 3524066 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 646, 400 micrograms q.i.d.
Number of subjects: 7
Study 3524066 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 646, 800 micrograms q.i.d.
Number of subjects: 7
Study 3524066 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin, 50 mg t.i.d. for 6 days
Number of subjects: 7
Study 30541530 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program and Nurse Home visit and Telephone follow‐up (ExN‐HaT)
Number of subjects: 222
Study 30541530 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Home visit and Telephone follow‐up (N‐HaT)
Number of subjects: 222
Study 30541530 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 222
Study 30541530 — intervention group
Group type: COMPARATOR
Intervention: Exercise program only
Number of subjects: 222
Study 27139431 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis vulgaris patients
Number of subjects: 100
Study 24481415 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic normothermia group with a target core temperature of 36.5°C using endovascular cooling
Number of subjects: 46
Study 24481415 — intervention group
Group type: COMPARATOR
Intervention: Conventional stepwise predefined fever management using antipyretic medication and surface cooling (Control)
Number of subjects: 46
Study 24481415 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Endovascular and Control)
Number of subjects: 46
Study 22751270 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment combining medical-nutritional interventions and family psychotherapy
Number of subjects: 28
Study 22751270 — intervention group
Group type: COMPARATOR
Intervention: Usual medical-nutritional intervention supported by psychiatric counselling
Number of subjects: 28
Study 20581776 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 160
Study 20581776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 160
Study 20581776 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 160
Study 20581776 — intervention group
Group type: COMPARATOR
Intervention: Saline (2 mL)
Number of subjects: 160
Study 17343310 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 0
Study 16295646 — intervention group
Group type: EXPERIMENTAL
Intervention: High communication performance
Number of subjects: 179
Study 16295646 — intervention group
Group type: COMPARATOR
Intervention: Adequate communication performance
Number of subjects: 179
Study 16295646 — intervention group
Group type: COMPARATOR
Intervention: Casual, business casual, formal dress styles and white coat (wearing or not)
Number of subjects: 179
Study 11814498 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microg)
Number of subjects: 109
Study 11814498 — intervention group
Group type: COMPARATOR
Intervention: PGE2 (2.5 mg)
Number of subjects: 109
Study 10364702 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise coaching and rehabilitation counseling (R) for 6 months
Number of subjects: 36
Study 10364702 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 36
Study 10364702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickness impact profile scores in PR
Number of subjects: 36
Study 10364702 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity correlations
Number of subjects: 36
Study 7591118 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwegian group B meningococcal OMV vaccine (3 doses)
Number of subjects: 27
Study 7591118 — intervention group
Group type: COMPARATOR
Intervention: Norwegian group B meningococcal OMV vaccine (2 doses)
Number of subjects: 27
Study 2186023 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam treatment group
Number of subjects: 23
Study 2186023 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment control group
Number of subjects: 23
Study 368045 — intervention group
Group type: EXPERIMENTAL
Intervention: Penfluridol (once weekly)
Number of subjects: 56
Study 368045 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (once daily)
Number of subjects: 56
Study 31814312 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed therapy (DOT) during the continuation phase of anti-TB therapy
Number of subjects: 1862
Study 31814312 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) change during anti-TB treatment
Number of subjects: 1862
Study 31814312 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+ count at TB diagnosis
Number of subjects: 1862
Study 28418209 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure band at the Neiguan point (P6) for 12 hours daily for three days
Number of subjects: 0
Study 28418209 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure band at the Neiguan point (P6)
Number of subjects: 0
Study 28418209 — intervention group
Group type: COMPARATOR
Intervention: Placebo wristband (non‐stimulating)
Number of subjects: 0
Study 26978418 — intervention group
Group type: EXPERIMENTAL
Intervention: ARTRA MSM (400 mg chondroitin sulfate, 500 mg glucosamine hydrochloride, 300 mg methylsulfonylmethane (MSM), and 10 mg sodium hyaluronate) taken as 2 tablets daily for one month, then 1 tablet daily
Number of subjects: 100
Study 26978418 — intervention group
Group type: COMPARATOR
Intervention: ARTRA (same composition as ARTRA MSM) taken in accordance with the same scheme
Number of subjects: 100
Study 24187120 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned Activities Training (PAT)
Number of subjects: 371
Study 24187120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular Phone-Enhanced Planned Activities Training (CPAT)
Number of subjects: 371
Study 24187120 — intervention group
Group type: EXPERIMENTAL
Intervention: PAT and CPAT
Number of subjects: 371
Study 24187120 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAT
Number of subjects: 371
Study 24187120 — intervention group
Group type: COMPARATOR
Intervention: Wait-List Control (WLC)
Number of subjects: 371
Study 21421039 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine-loaded lipid emulsion (VLE)
Number of subjects: 0
Study 21421039 — intervention group
Group type: COMPARATOR
Intervention: Commercial product, Navelbine(®) i.v. (VS)
Number of subjects: 0
Study 19393786 — intervention group
Group type: EXPERIMENTAL
Intervention: Roadside Impairment Testing Apparatus (RITA)
Number of subjects: 122
Study 19393786 — intervention group
Group type: COMPARATOR
Intervention: Field Impairment Tests (FIT)
Number of subjects: 122
Study 19393786 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal Gaze Nystagmus (HGN)
Number of subjects: 122
Study 15969860 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0
Study 12208595 — intervention group
Group type: COMPARATOR
Intervention: Plasma t‐PA concentration on day 1 of acute MI
Number of subjects: 106
Study 12208595 — intervention group
Group type: COMPARATOR
Intervention: Plasma PAI‐1 concentration on day 1 of acute MI
Number of subjects: 106
Study 12208595 — intervention group
Group type: COMPARATOR
Intervention: Plasma C‐reactive protein concentration on day 1 of acute MI
Number of subjects: 106
Study 12208595 — intervention group
Group type: COMPARATOR
Intervention: Plasma t‐PA concentration on day 28 after admission
Number of subjects: 106
Study 10075054 — intervention group
Group type: EXPERIMENTAL
Intervention: Proinflammatory activity in ARDS fluids
Number of subjects: 31
Study 10075054 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-2 levels in ARDS edema fluids
Number of subjects: 31
Study 10075054 — intervention group
Group type: EXPERIMENTAL
Intervention: Proinflammatory activity in plasma from ARDS patients
Number of subjects: 31
Study 10075054 — intervention group
Group type: EXPERIMENTAL
Intervention: Levels of procollagen peptide III in permeability edema fluids
Number of subjects: 31
Study 10075054 — intervention group
Group type: COMPARATOR
Intervention: SAPS II and LIS scores in ARDS patients
Number of subjects: 31
Study 8544139 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe-down rotation of a supporting platform
Number of subjects: 0
Study 8544139 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe-up rotation of a supporting platform
Number of subjects: 0
Study 8544139 — intervention group
Group type: COMPARATOR
Intervention: Stable frame holding condition
Number of subjects: 0
Study 8544139 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform displacement at 140 ms after go-signal
Number of subjects: 0
Study 8544139 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform displacement
Number of subjects: 0
Study 8544139 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition to a new, stabilized postural 'set'
Number of subjects: 0
Study 1761065 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg b.d. for 1 week
Number of subjects: 10
Study 1761065 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil administration
Number of subjects: 10
Study 1761065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7135175 — intervention group
Group type: EXPERIMENTAL
Intervention: choledochoduodenostomy (group A, 40 patients)
Number of subjects: 120
Study 7135175 — intervention group
Group type: COMPARATOR
Intervention: sphincteroplasty (group B, 40 patients)
Number of subjects: 120
Study 7135175 — intervention group
Group type: COMPARATOR
Intervention: T-tube drainage (group C, 40 patients)
Number of subjects: 120
Study 30680768 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept monotherapy (AM)
Number of subjects: 60
Study 30680768 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept plus pranoprofen (AP)
Number of subjects: 60
Study 30680768 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept plus nutraceutical (AN)
Number of subjects: 60
Study 29269717 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 78
Study 29269717 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone
Number of subjects: 78
Study 29269717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 25683116 — intervention group
Group type: EXPERIMENTAL
Intervention: larazotide acetate 0.5 mg 3 times daily
Number of subjects: 342
Study 25683116 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 342
Study 24804871 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol (250 mg) with 20 mg piperine
Number of subjects: 23
Study 24804871 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol (250 mg)
Number of subjects: 23
Study 24804871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 21519222 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron + Dexamethasone (8-mg dexamethasone + 0.075-mg palonosetron)
Number of subjects: 118
Study 21519222 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron alone (0.075 mg palonosetron)
Number of subjects: 118
Study 19242322 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractioned heparin (UFH) 500 units/hour for 7 days
Number of subjects: 319
Study 19242322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 19242322 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractioned heparin (UFH)
Number of subjects: 319
Study 17237216 — intervention group
Group type: EXPERIMENTAL
Intervention: Obtuse angle approach
Number of subjects: 83
Study 17237216 — intervention group
Group type: COMPARATOR
Intervention: Acute angle approach
Number of subjects: 83
Study 14666114 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐759274 40 mg daily
Number of subjects: 128
Study 14666114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 12146536 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD)
Number of subjects: 30
Study 12146536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9696260 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable membrane (Guidor)
Number of subjects: 40
Study 9696260 — intervention group
Group type: COMPARATOR
Intervention: Conventional flap therapy
Number of subjects: 40
Study 8123509 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterets and Ster-zac powder
Number of subjects: 100
Study 8123509 — intervention group
Group type: COMPARATOR
Intervention: Untreated umbilical cords
Number of subjects: 100
Study 2759945 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg, twice daily for 5 days)
Number of subjects: 5
Study 2759945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 785691 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrase (snake venom enzyme) administered daily for 3 weeks
Number of subjects: 10
Study 785691 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study 28319018 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum progesterone (≥4.6 nmol/l)
Number of subjects: 271
Study 28319018 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated progesterone level with rise in LH
Number of subjects: 271
Study 28319018 — intervention group
Group type: COMPARATOR
Intervention: Control group (no elevated progesterone)
Number of subjects: 271
Study 28319018 — intervention group
Group type: COMPARATOR
Intervention: Control group (no elevated progesterone with rise in LH)
Number of subjects: 271
Study 26087584 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant mesocarb
Number of subjects: 0
Study 26087584 — intervention group
Group type: EXPERIMENTAL
Intervention: Nootropic and anxiolytic fenibut
Number of subjects: 0
Study 26087584 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranquilizer fenazepam
Number of subjects: 0
Study 26087584 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-adrenoblocker proroxan
Number of subjects: 0
Study 24284358 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy (SET) after percutaneous transluminal angioplasty (PTA)
Number of subjects: 50
Study 24284358 — intervention group
Group type: COMPARATOR
Intervention: Control group (PTA alone)
Number of subjects: 50
Study 21533818 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (thrombopoietin receptor agonist)
Number of subjects: 197
Study 21533818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 19292211 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral total knee arthroplasty (TKA)
Number of subjects: 50